Dihydroartemisinin engages liver fatty acid binding protein and suppresses metastatic hepatocellular carcinoma growth

Dihydroartemisinin non-covalently binds liver fatty acid binding protein (FABP1) with micromolar affinity, acts as a FABP1-dependent peroxisome proliferator-activated receptor alpha agonist and inhibits metastatic hepatocellular carcinoma growth.

Automated summary

Dihydroartemisinin binds to liver fatty acid binding protein (FABP1) without forming a covalent bond. It acts as an agonist for peroxisome proliferator-activated receptor alpha (PPARα) which is dependent on FABP1, and inhibits the growth of metastatic hepatocellular carcinoma.